{"disease":{"id":"other-causes-of-cognitive-decline","name":"other causes of cognitive decline","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"florbetaben","indication_name":"other causes of cognitive decline","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neuraceq","generic_name":"FLORBETABEN","company_name":"Life Molecular","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":39,"revenue":null,"mechanism":""},{"drug_id":"florbetaben","indication_name":"other causes of cognitive decline","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neuraceq","generic_name":"FLORBETABEN","company_name":"Life Molecular","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":39,"revenue":null,"mechanism":""},{"drug_id":"flutemetamol","indication_name":"other causes of cognitive decline","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vizamyl","generic_name":"FLUTEMETAMOL","company_name":"Ge Healthcare","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":50,"revenue":null,"mechanism":"Vizamyl works by binding to amyloid plaques in the brain, allowing for visualization through positron emission tomography (PET) imaging."},{"drug_id":"flutemetamol","indication_name":"other causes of cognitive decline","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vizamyl","generic_name":"FLUTEMETAMOL","company_name":"Ge Healthcare","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":50,"revenue":null,"mechanism":"Vizamyl works by binding to amyloid plaques in the brain, allowing for visualization through positron emission tomography (PET) imaging."},{"drug_id":"florbetapir","indication_name":"other causes of cognitive decline","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amyvid","generic_name":"FLORBETAPIR","company_name":"Avid Radiopharms Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":45,"revenue":null,"mechanism":"Amyvid binds to beta-amyloid plaques in the brain, allowing for visualization of these plaques through PET imaging."},{"drug_id":"florbetapir","indication_name":"other causes of cognitive decline","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amyvid","generic_name":"FLORBETAPIR","company_name":"Avid Radiopharms Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":45,"revenue":null,"mechanism":"Amyvid binds to beta-amyloid plaques in the brain, allowing for visualization of these plaques through PET imaging."}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}